GRAIL Announces Significant Progress with Multi-Cancer Early Detection Test Including FDA Breakthrough Device Designation
Liquid biopsy company GRAIL announced today that its multi-cancer test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration. This investigational blood test is in development for the early detection of multiple cancer types in individuals aged 50 and over. The FDA...